Tamiflu US Press Conference

Tamiflu (oseltamivir) is a neuraminidase inhibitor, developed by Roche, for the treatment of seasonal and pandemic influenza. Yet for the first time a comprehensive review of the data, by independent researchers, has shown that the claims for Tamiflu’s effectiveness have been overestimated, and that harms have been underreported. Here is the audio of a recent press conference where researchers and the BMJ's editors describe the findings of that research, and the systematic regulatory failures those findings expose. Taking part were: Fiona Godlee - BMJ editor in chief Carl Heneghan - Director of Oxford University's Centre for Evidence Based Medicine Peter Doshi - Assistant Professor of Pharmaceutical Health Services Research Elizabeth Loder - The BMJ clinical epidemiology editor David Tovey - Editor in chief, Cochrane Library Ben Goldacre - Founder of the AllTrials campaign